Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 5/20 | 0.52 |
| ▸ | LGALS4 | P56470 | 4/20 | 0.52 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.49 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.49 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.43 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SYNJ2 | O15056 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1521368 | 1.00 | LGALS3 (0.52) | LGALS3LGALS4LGALS9LGALS1LGALS7; LGALS7B | |
| SCHEMBL12807943 | 1.00 | LGALS3 (0.52) | LGALS3LGALS4LGALS9LGALS1LGALS7; LGALS7B | |
| SCHEMBL1682180 | 1.00 | LGALS3 (0.52) | LGALS3LGALS4LGALS9LGALS1LGALS7; LGALS7B | |
| SCHEMBL9545439 | 1.00 | LGALS3 (0.52) | LGALS3LGALS4LGALS9LGALS1LGALS7; LGALS7B | |
| SCHEMBL12595600 | 1.00 | LGALS3 (0.52) | LGALS3LGALS4LGALS9LGALS1LGALS7; LGALS7B | |
| SCHEMBL24192986 | 1.00 | LGALS3 (0.52) | LGALS3LGALS4LGALS9LGALS1LGALS7; LGALS7B | |
| SCHEMBL14413230 | 1.00 | LGALS3 (0.52) | LGALS3LGALS4LGALS9LGALS1LGALS7; LGALS7B | |
| SCHEMBL19869143 | 1.00 | LGALS3 (0.52) | LGALS3LGALS4LGALS9LGALS1LGALS7; LGALS7B | |
| SCHEMBL7150482 | 0.93 | LGALS8 (0.53) | LGALS3LGALS4LGALS9LGALS1LGALS7; LGALS7B | |
| SCHEMBL8658236 | 0.93 | LGALS3 (0.46) | LGALS3LGALS4LGALS9LGALS1LGALS7; LGALS7B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2406270-B1 | METHOD FOR MANUFACTURING 4-FLUORO-4-DESOXY-ALPHA-D-GLUCOPYRANOSIDES | SANOFI SA (FR) | 2013-04-17 | — | — | EP | disclosed |
| US-20120270819-A1 | USE OF COMPOUNDS WITH SGLT-1/SGLT-2 INHIBITOR ACTIVITY FOR PRODUCING MEDICAMENTS FOR TREATMENT OF BONE DISEASE | SANOFI (FR) | 2012-10-25 | — | — | US | disclosed |
| EP-2482823-A2 | USE OF COMPOUNDS WITH SGLT-1/SGLT-2 INHIBITOR ACTIVITY FOR PRODUCING MEDICAMENTS FOR TREATMENT OF BONE DISEASES | SANOFI (FR) | 2012-08-08 | — | — | EP | disclosed |
| WO-2011039338-A2 | USE OF COMPOUNDS WITH SGLT-1/SGLT-2 INHIBITOR ACTIVITY FOR PRODUCING MEDICAMENTS FOR TREATMENT OF BONE DISEASES | SANOFI-AVENTIS (FR) | 2011-04-07 | — | — | WO | disclosed |
| US-7820804-B2 | Fluoroglycoside derivatives of pyrazoles, medicaments containing these compounds, and the use thereof | Sanofi-Aventia Deutschland GmbH (DE) | 2010-10-26 | — | — | US | disclosed |
| US-20070197623-A1 | NOVEL FLUOROGLYCOSIDE DERIVATIVES OF PYRAZOLES, MEDICAMENTS CONTAINING THESE COMPOUNDS, AND THE USE THEREOF | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-08-23 | — | — | US | disclosed |
| EP-1758914-A1 | NOVEL FLUOROGLYCOSIDE DERIVATIVES OF PYRAZOLES, MEDICAMENTS CONTAINING THESE COMPOUNDS, AND THE USE THEREOF | Sanofi-Aventis Deutschland GmbH (DE) | 2007-03-07 | — | — | EP | disclosed |
| WO-2005121161-A1 | NOVEL FLUOROGLYCOSIDE DERIVATIVES OF PYRAZOLES, MEDICAMENTS CONTAINING THESE COMPOUNDS, AND THE USE THEREOF | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270819-A1 | USE OF COMPOUNDS WITH SGLT-1/SGLT-2 INHIBITOR ACTIVITY FOR PRODUCING MEDICAMENTS FOR TREATMENT OF BONE DISEASE | SLC5A1, SLC5A2, SOST | LGALS3 240/4885LGALS4 199/4885LGALS9 272/4885 |
| US-20070197623-A1 | NOVEL FLUOROGLYCOSIDE DERIVATIVES OF PYRAZOLES, MEDICAMENTS CONTAINING THESE COMPOUNDS, AND THE USE THEREOF | DPP4, UGGT1, SLC5A2 | LGALS3 68/4885LGALS4 88/4885LGALS9 272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.